Inotersen, a 2′-O-methoxyethyl-modified ASO targeting both wild-type and mutant TTR in the liver, demonstrated positive outcomes in a 15-month phase 3 study for hereditary TTR amyloidosis polyneuropathy [126]. The gene discussed is TTR; the disease is amyloidosis.